E-LIB Suche - Ergebnisse für: Oriol, A.

1

The genomic profiling of high-risk smoldering myeloma patie..:

Medina-Herrera, A. ; Vazquez, I. ; Cuenca, I....
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

HPR9 Value Criteria for Outcomes Based Managed Entry Agreem..:

Poveda, J.L. ; Mateos, M.V. ; Trillo, J.L....
Value in Health. 26 (2023) 12 - p. S256 , 2023

Link: https://doi.org/10.1016/..

3

CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC)..:

Moreau, P. ; Usmani, S.Z. ; van de Donk, N.W.C.J....
Value in Health. 26 (2023) 12 - p. S31 , 2023

Link: https://doi.org/10.1016/..

4

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSE..:

van de Donk, N. ; Rasche, L. ; Touzeau, C....
HemaSphere. 7 (2023) S2 - p. 34-34 , 2023

Link: https://doi.org/10.1097/..

5

P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) ..:

Moreau, P. ; Usmani, S.Z. ; van de Donk, N.W.C.J....
Value in Health. 26 (2023) 12 - p. S5-S6 , 2023

Link: https://doi.org/10.1016/..

6

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED R..:

Minnema, M.C. ; Chari, A. ; Touzeau, C....
HemaSphere. 7 (2023) S2 - p. 26-27 , 2023

Link: https://doi.org/10.1097/..

7

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS..:

Dimopoulos, MA ; Oriol, A ; Nahi, H...
HemaSphere. 6 (2022) - p. 13-13 , 2022

Link: https://doi.org/10.1097/..

8

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY ..:

Quach, H. ; Parmar, G. ; Ocio, E. M....
HemaSphere. 6 (2022) - p. 835-836 , 2022

Link: https://doi.org/10.1097/..

9

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF ..:

van de Donk, N. W. ; Bahlis, N. ; Mateos, M.-V....
HemaSphere. 6 (2022) - p. 84-85 , 2022

Link: https://doi.org/10.1097/..

10

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS ..:

Usmani, S. Z. ; Mielnik, M. ; Koh, Y....
HemaSphere. 6 (2022) - p. 832-833 , 2022

Link: https://doi.org/10.1097/..

11

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A..:

Martínez-López, J. ; Moreau, P. ; Usmani, S. Z....
HemaSphere. 6 (2022) - p. 811-812 , 2022

Link: https://doi.org/10.1097/..

12

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ..:

Suvannasankha, A. ; Bahlis, N. ; Trudel, S....
HemaSphere. 6 (2022) - p. 830-831 , 2022

Link: https://doi.org/10.1097/..

13

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUM..:

Rodriguez-Otero, P ; Dholaria, B ; Askari, E...
HemaSphere. 6 (2022) - p. 7-8 , 2022

Link: https://doi.org/10.1097/..

14

Corrigendum to P-207: A multi-center, phase 1b study to ass..:

Moreau, Philippe ; Parmar, Gurdeep ; Prince, Miles...
Clinical Lymphoma Myeloma and Leukemia. , 2022

Link: https://doi.org/10.1016/..

15

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS ..:

Rosinol, L. ; Usmani, S. Z. ; Bahlis, N....
HemaSphere. 6 (2022) - p. 1885-1886 , 2022

Link: https://doi.org/10.1097/..